Lisa Conroy

Lisa Conroy is the Director of Communications at Antidote. She is a seasoned health communications strategist dedicated to understanding the reasons people make the health choices they do, and determining what that means in terms of how scientific data should be communicated. Prior to her role at Antidote, Lisa ran the TEDMED Great Challenges program, a public health initiative funded by RWJF. She also has experience working in pharmaceutical public relations in the areas of respiratory diseases, oncology, and HIV. Lisa holds an MPH from Columbia and a BA in English and International Studies from Northwestern.

Patient recruitment: Today’s trends, tomorrow’s potential [interview with ACRPtv]

By some estimations, 80% of clinical trials are delayed or closed because researchers can’t find enough patients to take part in their clinical trials. This, of course, means that trial sponsors are losing money and sites are wasting time screening ineligible patients. But, it also means that countless patients continue to wait for new and potentially better treatment options.

Continue reading

How to find and join lupus support groups

Living with lupus can be difficult. It’s an “invisible illness” — meaning those around you can’t see your fatigue or your muscle and joint pain or any of the many other symptoms. This can be a lonely experience, and that’s why it’s so important for people with lupus to connect with others who have the condition as well. 

Continue reading

Why your clinical trial advertising might be missing the mark

Are you spending time and money on clinical trial advertising that’s not delivering? It can be frustrating to put resources into spreading the word about your study, only to find that the patients who make it to your sites are not right for your trial. According to a survey Antidote conducted of 4,000+ patients, 52% of patients found out about clinical trial opportunities through an ...

Continue reading

The evolving role of partnerships in clinical trial patient engagement

An interview with Lindsey Wahlstrom-Edwards, Head of Partnerships at Antidote

Continue reading

How we cut our expected referral timeline in half [patient recruitment case study]

Idiopathic pulmonary fibrosis (IPF) is a progressive disease that causes scarring of the lungs. Over time, the scarring worsens and it can become difficult to breathe. IPF has no cure and limited treatment options, making clinical research especially critical. In this case study, a pharma company approached Antidote to identify 600 IPF patients who would be eligible for their study in just six ...

Continue reading

Patient engagement during COVID-19 [whitepaper]

Does a health crisis change digital engagement behaviors? How should digital marketers respond?

Continue reading

A delicate balance: How clinical trial patient engagement benefits from technology with a human touch [Whitepaper]

Can we apply customer service models to healthcare? And what would that mean for clinical trial patient recruitment? 

Continue reading

7 Things You Need to Know If You Have Multiple Sclerosis [Updated]

Being diagnosed with multiple sclerosis (MS) can feel overwhelming and isolating. It's true that the neurodegenerative disease involves challenging symptoms, but knowing what to expect and how to tap into available resources can help. 

Continue reading

Top 3 clinical trial recruitment challenges – and how to beat them

Every clinical trial planning process hits bumps in the road now and then, but a few common clinical trial recruitment challenges consistently slow the research process and keep new treatments out of patient hands. The solutions to the most common challenges aren’t necessarily simple, but they do start from the most important place – the patient perspective. 

Continue reading

Digital patient recruitment: How to reach the right patients

Ask any two trial sponsors how they feel about digital patient recruitment, and you’re likely to get two very different responses. Some have a positive experience and are able to reach their trial’s goals faster than they have with traditional methods. But others will warn you against a digital approach, citing unresponsive patients and wasted budget. It’s true that digital patient recruitment, ...

Continue reading

Get our latest posts in your inbox.